{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:13:08Z","timestamp":1790485988410,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068632"],"award-info":[{"award-number":["UM1AI068632"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068616"],"award-info":[{"award-number":["UM1AI068616"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI106716"],"award-info":[{"award-number":["UM1AI106716"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p><jats:italic>We set out to evaluate the<\/jats:italic> effect of postnatal exposure to tenofovir-containing antiretroviral therapy on bone mineral density among breastfeeding women living with HIV.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Design<\/jats:title>\n<jats:p>IMPAACT P1084s is a sub-study of the PROMISE randomized trial conducted in four African countries (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link> number NCT01066858).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>IMPAACT P1084s enrolled eligible mother-infant pairs previously randomised in the PROMISE trial at one week after delivery to receive either maternal antiretroviral therapy (Tenofovir disoproxil fumarate \/ Emtricitabine + Lopinavir\/ritonavir\u2013maternal TDF-ART) or administer infant nevirapine, with no maternal antiretroviral therapy, to prevent breastmilk HIV transmission. Maternal lumbar spine and hip bone mineral density were measured using dual-energy x-ray absorptiometry (DXA) at postpartum weeks 1 and 74. We studied the effect of the postpartum randomization on percent change in maternal bone mineral density in an intention-to-treat analysis with a t-test; mean and 95% confidence interval (95%CI) are presented.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 398\/400 women included in this analysis, baseline age, body-mass index, CD4 count, mean bone mineral density and alcohol use were comparable between study arms. On average, maternal lumbar spine bone mineral density declined significantly through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference (95%CI) -2.86 (-4.03, -1.70) percentage points (p-value &lt;0.001). Similarly, maternal hip bone mineral density declined significantly more through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference -2.29% (-3.20, -1.39) (p-value &lt;0.001). Adjusting for covariates did not change the treatment effect.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Bone mineral density decline through week 74 postpartum was greater among breastfeeding HIV-infected women randomized to receive maternal TDF-ART during breastfeeding compared to those mothers whose infants received nevirapine prophylaxis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0246272","type":"journal-article","created":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T19:08:58Z","timestamp":1612724938000},"page":"e0246272","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3566-1688","authenticated-orcid":true,"given":"Lynda","family":"Stranix-Chibanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camlin","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Sebikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-8839","authenticated-orcid":true,"given":"Jim","family":"Aizire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufia","family":"Dadabhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Admire","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Mukwasi-Kahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tichaona","family":"Vhembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avy","family":"Violari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Theron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhayandre","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-9808","authenticated-orcid":true,"given":"Lynne M.","family":"Mofenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Glenn","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Siberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the PROMISE P1084s study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"issue":"1","key":"pone.0246272.ref001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1385\/ENDO:17:1:49","article-title":"Bone mineral changes during pregnancy and lactation","volume":"17","author":"H. Kalkwarf","year":"2002","journal-title":"Endocrine"},{"issue":"2","key":"pone.0246272.ref002","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.00027.2015","article-title":"Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery","volume":"96","author":"C. S. Kovacs","year":"2016","journal-title":"Physiol. Rev."},{"issue":"2","key":"pone.0246272.ref003","doi-asserted-by":"crossref","first-page":"50","DOI":"10.11599\/germs.2016.1089","article-title":"Original article Low bone mineral density and associated risk factors in HIV-infected patients","volume":"6","author":"C.-E. Chitu-Tisu","year":"2016","journal-title":"GERMS"},{"issue":"4","key":"pone.0246272.ref004","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","article-title":"Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals","volume":"36","author":"K. Mondy","year":"2003","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"pone.0246272.ref005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/infdis\/jiu499","article-title":"Low Bone Mineral Density in Patients With Well-Suppressed HIV Infection: Association With Body Weight, Smoking, and Prior Advanced HIV Disease","volume":"211","author":"K. W. Kooij","year":"2015","journal-title":"Ournal Infect. Dis."},{"key":"pone.0246272.ref006","first-page":"e89","article-title":"Low bone mineral density among HIV-infected patients in Brazil","volume":"59","author":"S D. C. da","year":"2017","journal-title":"Rev. Inst. Med. Trop. S\u00e3o Paulo"},{"issue":"15","key":"pone.0246272.ref007","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/QAD.0b013e32836378c3","article-title":"Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia","volume":"27","author":"L. Assoumou","year":"2013","journal-title":"AIDS Lond. Engl."},{"key":"pone.0246272.ref008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1468-1293.2007.00525.x","article-title":"Evolution of bone mineral density in AIDS patients on treatment with zidovudine \/ lamivudine plus abacavir or lopinavir \/ ritonavir","volume":"9","author":"P. Rivas","year":"2008","journal-title":"HIV Med."},{"key":"pone.0246272.ref009","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11657-015-0238-z","article-title":"Association between HIV infection and bone mineral density in climacteric women","volume":"10","author":"D. C. Gomes","year":"2015","journal-title":"Arch. Osteoporos."},{"issue":"Suppl 2","key":"pone.0246272.ref010","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1086\/367566","article-title":"Emerging bone problems in patients infected with human immunodeficiency virus","volume":"36","author":"K. Mondy","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0246272.ref011","doi-asserted-by":"crossref","DOI":"10.1097\/00002030-200402200-00014","article-title":"Reduced bone density in HIV-infected women","volume":"18","author":"S. E. Dolan","year":"2004","journal-title":"AIDS"},{"issue":"9","key":"pone.0246272.ref012","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jbmr.3183","article-title":"Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial","volume":"32","author":"J. F. Hoy","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"pone.0246272.ref013","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","article-title":"Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen","volume":"51","author":"T. T. Brown","year":"2009","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"issue":"5","key":"pone.0246272.ref014","first-page":"224","article-title":"Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142","volume":"14","author":"J. S. Huang","year":"2013","journal-title":"AIDS Clinical Trials Group AHIV Clin. Trials"},{"issue":"12","key":"pone.0246272.ref015","doi-asserted-by":"crossref","first-page":"e0144286","DOI":"10.1371\/journal.pone.0144286","article-title":"Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans","volume":"10","author":"J. Dave","year":"2015","journal-title":"PLoS ONE"},{"issue":"3","key":"pone.0246272.ref016","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/COH.0000000000000260","article-title":"The protease inhibitors and HIV-associated bone loss","volume":"11","author":"C. A. Moran","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"4","key":"pone.0246272.ref017","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jpeds.2007.12.020","article-title":"Decreased Bone Mineral Density with Off-Label Use of Tenofovir in Children and Adolescents Infected with Human Immunodeficiency Virus","volume":"152","author":"J. B. Purdy","year":"2008","journal-title":"J. Pediatr."},{"key":"pone.0246272.ref018","first-page":"1","article-title":"Switch from tenofovir disoproxil fumarate combination to dolutegravir plus rilpivirine improves parameters of bone health","author":"G. A. Mccomsey","year":"2017","journal-title":"AIDS"},{"issue":"4","key":"pone.0246272.ref019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","article-title":"Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment","volume":"34","author":"E. DeJesus","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"10","key":"pone.0246272.ref020","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","article-title":"Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial","volume":"6","author":"F. Maggiolo","year":"2019","journal-title":"Lancet HIV"},{"issue":"3","key":"pone.0246272.ref021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/QAI.0000000000000858","article-title":"Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis","volume":"71","author":"B. G. Mirembe","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr. 1999"},{"issue":"4","key":"pone.0246272.ref022","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/civ324","article-title":"Effects of Emtricitabine\/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"61","author":"K. Mulligan","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"issue":"Suppl 1","key":"pone.0246272.ref023","doi-asserted-by":"crossref","first-page":"A230","DOI":"10.1136\/gut.2011.239301.486","article-title":"Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit?","volume":"60","author":"U. S. Gill","year":"2011","journal-title":"Gut"},{"issue":"4","key":"pone.0246272.ref024","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/egh.12.19","article-title":"Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B","volume":"6","author":"M. Buti","year":"2012","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"pone.0246272.ref025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAI.0000000000001591","article-title":"Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men","volume":"77","author":"K. M. Erlandson","year":"2018","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"pone.0246272.ref026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/JCD:2:1:79","article-title":"Causes of Secondary Osteoporosis","volume":"2","author":"Z. C. Orlic","year":"1999","journal-title":"J. Clin. Densitom."},{"issue":"3","key":"pone.0246272.ref027","doi-asserted-by":"crossref","first-page":"161","DOI":"10.6118\/jmm.2016.22.3.161","article-title":"Effect of Multiparity and Prolonged Lactation on Bone Mineral Density","volume":"22","author":"N. Sharma","year":"2016","journal-title":"J. Menopausal Med."},{"issue":"1","key":"pone.0246272.ref028","first-page":"52","article-title":"Bone mineral changes during and after lactation","volume":"94","author":"F. Polatti","year":"1999","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"pone.0246272.ref029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11657-017-0368-6","article-title":"Spine bone mineral density increases after 6 months of exclusive lactation, even in women who keep breastfeeding","author":"S. Cooke-Hubley","year":"2017","journal-title":"Arch. Osteoporos."},{"issue":"4","key":"pone.0246272.ref030","first-page":"608","article-title":"Bone mineral changes during and after lactation","volume":"94","author":"M. A. Laskey","year":"1999","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"pone.0246272.ref031","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0029-7844(95)00083-4","article-title":"Bone mineral loss during lactation and recovery after weaning","volume":"86","author":"H. J. Kalkwarf","year":"1995","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"pone.0246272.ref032","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11904-016-0336-6","article-title":"Bone Loss Among Women Living With HIV","volume":"13","author":"M. N. Weitzmann","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"pone.0246272.ref033","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2014.12.013","article-title":"Parity, lactation, bone strength, and 16-year fracture risk in adult women: findings from the Study of Women\u2019s Health Across the Nation (SWAN)","volume":"73","author":"T. Mori","year":"2015","journal-title":"Bone"},{"issue":"4","key":"pone.0246272.ref034","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jbmr.3090","article-title":"The Skeleton Is a Storehouse of Mineral That Is Plundered During Lactation and (Fully?) Replenished Afterwards","volume":"32","author":"C. S. Kovacs","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"pone.0246272.ref035","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jbmr.3018","article-title":"Irreversible Deterioration of Cortical and Trabecular Microstructure Associated With Breastfeeding","volume":"32","author":"\u00c5. Bj\u00f8rnerem","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"pone.0246272.ref036","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/COH.0000000000000274","article-title":"Bone health and HIV in resource-limited settings: a scoping review","volume":"11","author":"F. K. Matovu","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"pone.0246272.ref037","article-title":"Changes in Bone Mineral Density During and After Lactation in Ugandan Women With HIV on Tenofovir-Based Antiretroviral Therapy","author":"F. Nabwire","year":"2020","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"pone.0246272.ref038","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/QAI.0000000000001612","article-title":"\u201cPrevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE)","volume":"77","author":"P. M. Flynn","year":"2018","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"issue":"18","key":"pone.0246272.ref039","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention","volume":"375","author":"M. Fowler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"pone.0246272.ref040","unstructured":"T. Taha, \u201cComparing maternal triple antiretrovirals (mART) and infant nevirapine (iNVP) prophylaxis for the prevention of mother-to-child transmission (MTCT) of HIV during breastfeeding (BF),\u201d presented at the 21st International AIDS Conference (AIDS 2016), Durban, South Africa, Jul. 2016."},{"issue":"5","key":"pone.0246272.ref041","doi-asserted-by":"crossref","first-page":"e0176009","DOI":"10.1371\/journal.pone.0176009","article-title":"Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 \u2265 400 cells\/mm(3)","volume":"12","author":"J. S. Currier","year":"2017","journal-title":"PLoS ONE"},{"issue":"9","key":"pone.0246272.ref042","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","volume":"373","author":"INSIGHT START Study Group","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"pone.0246272.ref043","doi-asserted-by":"crossref","unstructured":"F. K. Matovu et al., \u201cDepo-Provera worsens bone loss with TDF-containing ART initiation in young women.,\u201d in Abstract Supplement Oral Abstracts from the 23rd International AIDS Conference, Virtual, Jul. 2020, vol. OAB0105, https:\/\/doi.org\/10.1002\/jia2.25547.","DOI":"10.1002\/jia2.25547"},{"issue":"6","key":"pone.0246272.ref044","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15284336.2016.1243363","article-title":"Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection","volume":"17","author":"R. Bedimo","year":"2016","journal-title":"HIV Clin. Trials"},{"issue":"9987","key":"pone.0246272.ref045","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"P. E. Sax","year":"2015","journal-title":"The Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T19:09:31Z","timestamp":1612724971000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246272"}},"subtitle":[],"editor":[{"given":"Esteban","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246272","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]}}}